<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - 08/26/2024</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body><h1 class="h1center">Progress note - 08/26/2024</h1><table class="header_table"><tr><td class="td_header_role_name"><span class="td_label">Patient</span></td><td class="td_header_role_value">Martin Rife</td></tr><tr><td class="td_header_role_name"><span class="td_label">Date of birth</span></td><td class="td_header_role_value">March 12, 1961 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Current Gender</span></td><td class="td_header_role_value">Male</td></tr><tr><td class="td_header_role_name"><span class="td_label">Race(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>White</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Ethnicity</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>Refused to Report</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Language(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>English (Preferred)</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Postal Address:<br/>10938 N 29TH ST<br/>TAMPA, FL 33612-3850, US<br/><br/> Postal Address:<br/>1813 E 109th Ave<br/>Tampa, FL 33612, US<br/><br/>Primary Home Phone:  813-638-2969<br/>Mobile Phone:  813-638-2969<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Patient IDs</span></td><td class="td_header_role_value">233694 2.16.840.1.113883.4.391.327187<br/>233694 2.16.840.1.113883.4.391.327187.1<br/></td></tr></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document Id</span></td><td class="td_header_role_value">c1a5f3fb-d201-4c92-99db-1ac082f34204 2.16.840.1.113883.4.391</td></tr><tr><td class="td_header_role_name"><span class="td_label">Document Created:</span></td><td class="td_header_role_value">August 29, 2024, 16:02:40 -0400 </td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Performer (primary care physician)</span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Jobse Lebron Perez</td></tr><tr><td class="td_header_role_value internal_format">320 W FLETCHER AVE<br/>STE 101<br/>TAMPA, FL 33612-3400, US<br/><br/>Tel:  813-374-9266<br/></td></tr></tbody></table></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Author</span></td><td class="td_header_role_value">eClinicalWorks</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"><br/><br/><br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Encounter Id</span></td><td class="td_header_role_value">21865458 2.16.840.1.113883.4.391.327187</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Type</span></td><td class="td_header_role_value">ambulatory</td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Date</span></td><td class="td_header_role_value"> From August 26, 2024, 09:00:00   to August 26, 2024, 09:20:00  </td></tr><tr><td class="td_header_role_name"><span class="td_label">Encounter Location</span></td><td class="td_header_role_value">id:  2.16.840.1.113883.4.391.327187</td></tr><tr><td class="td_header_role_name"><span class="td_label">Responsible party</span></td><td class="td_header_role_value">Jobse Lebron Perez</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">320 W FLETCHER AVE<br/>STE 101<br/>TAMPA, FL 33612-3400, US<br/><br/>Tel:  813-374-9266<br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Emergency contact</span></td><td class="td_header_role_value">Christall Arned<br/><br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"><br/><br/>Tel:  813-900-3123<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Guarantor</span></td><td class="td_header_role_value">Martin Rife<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"><br/><br/>Tel:  813-638-2969<br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document maintained by</span></td><td class="td_header_role_value">MyCare Medical Group</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value">1785 NORTHPOINTE PKWY<br/>STE 300<br/>LUTZ, FL 33558-5742, US<br/><br/>Tel:  813-536-7277<br/></td></tr></tbody></table><h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Allergies</a></li><li><a href="#id2">REASON FOR VISIT</a></li><li><a href="#id3">Medications</a></li><li><a href="#id4">Social History</a></li><li><a href="#id5">Vital Signs</a></li><li><a href="#id6">Encounters</a></li><li><a href="#id7">Assessments</a></li><li><a href="#id8">Plan Of Treatment</a></li><li><a href="#id9">Procedure Notes</a></li><li><a href="#id10">Progress Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Allergies</a></h3><div><span class="content_span">No Known Allergies</span></div><h3><a name="id2" href="#toc">REASON FOR VISIT</a></h3><div>EOV with labs</div><h3><a name="id3" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Gabapentin 300 MG</td><td ID="instruction1">take one capsule by mouth 3 times daily Orally every 8 hrs for as needed</td><td ID="medication1notes">PM</td><td/><td/><td>Active</td></tr><tr><td ID="medication2">Sertraline HCl 100 MG</td><td ID="instruction2">TAKE ONE TABLET BY MOUTH TWICE A DAY Orally Twice a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication3">Fenofibrate 160 MG</td><td ID="instruction3">TAKE ONE TABLET BY MOUTH DAILY WITH FOOD Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">Atorvastatin Calcium 80 MG</td><td ID="instruction4">1 tablet Orally Once a night for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">risperiDONE 4 MG</td><td ID="instruction5">1 tablet Orally Twice a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication6">Albuterol Sulfate HFA 108 (90 Base) MCG/ACT</td><td ID="instruction6">INHALE 2 PUFFS BY MOUTH EVERY FOUR HOURS every 4 hrs</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication7">Lisinopril 5 MG</td><td ID="instruction7">1 tablet Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication8">Niacin ER 1000 MG</td><td ID="instruction8">1 tablet with food Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication9">Naloxone HCl 4 MG/0.1ML</td><td ID="instruction9">Naloxone intranasal Nasally as needed</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication10">Mirtazapine 30 MG</td><td ID="instruction10">1 tablet at bedtime Orally Once a day for 30 days</td><td/><td>10/31/2023</td><td/><td>Active</td></tr><tr><td ID="medication11">Aspirin 325 MG</td><td ID="instruction11">1 tablet Orally Once a day</td><td/><td/><td/><td>Unknown</td></tr><tr><td ID="medication12">Banophen 50 MG</td><td ID="instruction12">TAKE 2 CAPSULES BY MOUTH DAILY for 90</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication13">oxyCODONE-Acetaminophen 5-325 MG</td><td ID="instruction13">1 tablet as needed Orally every 6 hrs</td><td ID="medication13notes">PM</td><td/><td/><td>Active</td></tr><tr><td ID="medication14">risperiDONE 4 MG</td><td ID="instruction14">TAKE 1 TABLET BY MOUTH TWICE A DAY Orally twice a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication15">Diclofenac Sodium 75 MG</td><td ID="instruction15">1 tablet Orally Twice a day for 90 days</td><td/><td>10/31/2023</td><td/><td>Active</td></tr><tr><td ID="medication16">Albuterol Sulfate HFA 108 (90 Base) MCG/ACT</td><td ID="instruction16">INHALE 2 PUFFS BY MOUTH EVERY FOUR HOURS for 50</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Social History</a></h3><div><span class="content_span">Sex Assigned At Birth:</span><table width="100%" border="1"><thead><tr><th>Social History Observation</th><th>Description</th></tr></thead><tbody><tr><td ID="BirthSexInfo">Sex Assigned At Birth</td><td>Male</td></tr></tbody></table></div><h3><a name="id5" href="#toc">Vital Signs</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Temperature</th><td>97.9 degrees Fahrenheit</td><td>08/26/2024</td></tr><tr><th ID="vital2">Blood pressure systolic</th><td>112 mm Hg</td><td>08/26/2024</td></tr><tr><th ID="vital3">Blood pressure diastolic</th><td>74 mm Hg</td><td>08/26/2024</td></tr><tr><th ID="vital4">Heart Rate</th><td>68 /min</td><td>08/26/2024</td></tr><tr><th ID="vital5">Respiratory Rate</th><td>16 /min</td><td>08/26/2024</td></tr><tr><th ID="vital6">Height</th><td>72 in</td><td>08/26/2024</td></tr><tr><th ID="vital7">Weight</th><td>222 lbs</td><td>08/26/2024</td></tr><tr><th ID="vital8">BMI</th><td>30.11 kg/m2</td><td>08/26/2024</td></tr><tr><th ID="vital9">Oximetry</th><td>97 %</td><td>08/26/2024</td></tr><tr><th ID="vital10">Weight-kg</th><td>100.7 kg</td><td>08/26/2024</td></tr></tbody></table></div><h3><a name="id6" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>MCM Tampa Fletcher Ave</td><td>320 W FLETCHER AVE STE 101 TAMPA, FL 33612-3400</td><td>08/26/2024</td><td>Jobse Lebron Perez</td><td>Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease I12.9 ; Chronic viral hepatitis C B18.2 ; Mixed hyperlipidemia E78.2 ; Hypercalcemia E83.52 ; Smoker F17.200 ; Other specified types of schizophrenia, chronic condition F20.89 ; Bipolar 1 disorder, depressed F31.9 ; Anxiety state F41.1 ; Primary insomnia F51.01 ; Chronic pain syndrome G89.4 ; PVD (peripheral vascular disease) I73.9 ; Chronic airway obstruction, not elsewhere classified J44.9 ; Primary osteoarthritis involving multiple joints M15.0 ; Primary osteoarthritis of left knee M17.12 ; Cervical radiculopathy due to degenerative joint disease of spine M47.22 ; Spondylosis without myelopathy or radiculopathy, lumbosacral region M47.817 ; Displacement of lumbar intervertebral disc M51.26 ; Lumbago with sciatica, right side M54.41 ; Lumbago with sciatica, left side M54.42 ; Muscle spasm M62.838 ; CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min N18.2 ; Pre-diabetes R73.03 ; Other long term (current) drug therapy Z79.899 ; Disc disease, degenerative, cervical M50.30 ; Opiate dependence F11.20 and Microalbuminuria R80.9</td></tr></tbody></table></div><h3><a name="id7" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th></tr></thead><tbody><tr><td ID="ref1">08/26/2024</td><td>Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease (ICD-10 - I12.9)</td><td>CKD stage 2</td><td>Low Na diet</td><td/></tr><tr><td ID="ref2">08/26/2024</td><td>Chronic viral hepatitis C (ICD-10 - B18.2)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref3">08/26/2024</td><td>Mixed hyperlipidemia (ICD-10 - E78.2)</td><td/><td>Low fat diet</td><td/></tr><tr><td ID="ref4">08/26/2024</td><td>Hypercalcemia (ICD-10 - E83.52)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref5">08/26/2024</td><td>Smoker (ICD-10 - F17.200)</td><td/><td>Patient counseled and Educated on dangers of tobacco use and urged him to decrease smoking and then to quit; patient not ready to quit yet</td><td/></tr><tr><td ID="ref6">08/26/2024</td><td>Other specified types of schizophrenia, chronic condition (ICD-10 - F20.89)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref7">08/26/2024</td><td>Bipolar 1 disorder, depressed (ICD-10 - F31.9)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref8">08/26/2024</td><td>Anxiety state (ICD-10 - F41.1)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref9">08/26/2024</td><td>Primary insomnia (ICD-10 - F51.01)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref10">08/26/2024</td><td>Chronic pain syndrome (ICD-10 - G89.4)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref11">08/26/2024</td><td>PVD (peripheral vascular disease) (ICD-10 - I73.9)</td><td/><td>ASA</td><td/></tr><tr><td ID="ref12">08/26/2024</td><td>Chronic airway obstruction, not elsewhere classified (ICD-10 - J44.9)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref13">08/26/2024</td><td>Primary osteoarthritis involving multiple joints (ICD-10 - M15.0)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref14">08/26/2024</td><td>Primary osteoarthritis of left knee (ICD-10 - M17.12)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref15">08/26/2024</td><td>Cervical radiculopathy due to degenerative joint disease of spine (ICD-10 - M47.22)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref16">08/26/2024</td><td>Spondylosis without myelopathy or radiculopathy, lumbosacral region (ICD-10 - M47.817)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref17">08/26/2024</td><td>Displacement of lumbar intervertebral disc (ICD-10 - M51.26)</td><td>Florida PM notes dated 07/12/2022</td><td>Monitor for changes</td><td/></tr><tr><td ID="ref18">08/26/2024</td><td>Lumbago with sciatica, right side (ICD-10 - M54.41)</td><td/><td>Continue current treatment</td><td/></tr><tr><td ID="ref19">08/26/2024</td><td>Lumbago with sciatica, left side (ICD-10 - M54.42)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref20">08/26/2024</td><td>Muscle spasm (ICD-10 - M62.838)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref21">08/26/2024</td><td>CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min (ICD-10 - N18.2)</td><td>GFR 67</td><td>Drink plenty of water</td><td/></tr><tr><td ID="ref22">08/26/2024</td><td>Pre-diabetes (ICD-10 - R73.03)</td><td/><td>diabetic diet and exercise</td><td/></tr><tr><td ID="ref23">08/26/2024</td><td>Other long term (current) drug therapy (ICD-10 - Z79.899)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref24">08/26/2024</td><td>Disc disease, degenerative, cervical (ICD-10 - M50.30)</td><td/><td>Monitor for changes</td><td/></tr><tr><td ID="ref25">08/26/2024</td><td>Opiate dependence (ICD-10 - F11.20)</td><td/><td><p>1) Drug has been taken for lager amount or over longer period than was intended</p><p>2) Persistent desire or unsuccessful efforts to cut down or control use</p><p>3) Craving or strong desire or urge to use the drug</p><p>4) continued use despite knowledge of having a persistent or recurrent physical or phychological problem that is likely caused or exacerbated by the drug.</p></td><td/></tr><tr><td ID="ref26">08/26/2024</td><td>Microalbuminuria (ICD-10 - R80.9)</td><td/><td>Monitor for changes</td><td/></tr></tbody></table></div><h3><a name="id8" href="#toc">Plan Of Treatment</a></h3><div><span class="content_span">Medication</span><table width="100%" border="1"><thead><tr><th>Medication Name</th><th>Sig</th><th>Start Date</th><th>Stop Date</th><th>Notes</th></tr></thead><tbody><tr><td ID="potMeds1">Gabapentin 300 MG</td><td>take one capsule by mouth 3 times daily Orally every 8 hrs for as needed</td><td/><td/><td>PM</td></tr><tr><td ID="potMeds2">Sertraline HCl 100 MG</td><td>TAKE ONE TABLET BY MOUTH TWICE A DAY Orally Twice a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds3">Fenofibrate 160 MG</td><td>TAKE ONE TABLET BY MOUTH DAILY WITH FOOD Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds4">Atorvastatin Calcium 80 MG</td><td>1 tablet Orally Once a night for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds5">risperiDONE 4 MG</td><td>1 tablet Orally Twice a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds6">Albuterol Sulfate HFA 108 (90 Base) MCG/ACT</td><td>INHALE 2 PUFFS BY MOUTH EVERY FOUR HOURS every 4 hrs</td><td/><td/><td/></tr><tr><td ID="potMeds7">Lisinopril 5 MG</td><td>1 tablet Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds8">Niacin ER 1000 MG</td><td>1 tablet with food Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds9">Naloxone HCl 4 MG/0.1ML</td><td>Naloxone intranasal Nasally as needed</td><td/><td/><td/></tr><tr><td ID="potMeds10">oxyCODONE-Acetaminophen 5-325 MG</td><td>1 tablet as needed Orally every 6 hrs</td><td/><td/><td>PM</td></tr></tbody></table><span class="content_span">Treatment Notes</span><table width="100%" border="1"><thead><tr><th>Assessment</th><th>Notes</th></tr></thead><tbody><tr><td ID="instructionpot1">Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease</td><td>Low Na diet</td></tr><tr><td ID="instructionpot2">Chronic viral hepatitis C</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot3">Mixed hyperlipidemia</td><td>Low fat diet</td></tr><tr><td ID="instructionpot4">Hypercalcemia</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot5">Smoker</td><td>Patient counseled and Educated on dangers of tobacco use and urged him to decrease smoking and then to quit; patient not ready to quit yet</td></tr><tr><td ID="instructionpot6">Other specified types of schizophrenia, chronic condition</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot7">Bipolar 1 disorder, depressed</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot8">Anxiety state</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot9">Primary insomnia</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot10">Chronic pain syndrome</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot11">PVD (peripheral vascular disease)</td><td>ASA</td></tr><tr><td ID="instructionpot12">Chronic airway obstruction, not elsewhere classified</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot13">Primary osteoarthritis involving multiple joints</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot14">Primary osteoarthritis of left knee</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot15">Cervical radiculopathy due to degenerative joint disease of spine</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot16">Spondylosis without myelopathy or radiculopathy, lumbosacral region</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot17">Displacement of lumbar intervertebral disc</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot18">Lumbago with sciatica, right side</td><td>Continue current treatment</td></tr><tr><td ID="instructionpot19">Lumbago with sciatica, left side</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot20">Muscle spasm</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot21">CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min</td><td>Drink plenty of water</td></tr><tr><td ID="instructionpot22">Pre-diabetes</td><td>diabetic diet and exercise</td></tr><tr><td ID="instructionpot23">Other long term (current) drug therapy</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot24">Disc disease, degenerative, cervical</td><td>Monitor for changes</td></tr><tr><td ID="instructionpot25">Opiate dependence</td><td><p>1) Drug has been taken for lager amount or over longer period than was intended</p><p>2) Persistent desire or unsuccessful efforts to cut down or control use</p><p>3) Craving or strong desire or urge to use the drug</p><p>4) continued use despite knowledge of having a persistent or recurrent physical or phychological problem that is likely caused or exacerbated by the drug.</p></td></tr><tr><td ID="instructionpot26">Microalbuminuria</td><td>Monitor for changes</td></tr></tbody></table><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="nextAppt">Follow Up: 3 Months,on Regular Scheduled OV, Reason: Follow-up of chronic conditions</td></tr><tr><td ID="futureAppt1">Provider Name:Jobse Lebron Perez, 11/19/2024 08:30:00 AM, 320 W FLETCHER AVE, STE 101, TAMPA, FL, 33612-3400, 813-374-9266</td></tr><tr><td ID="futureAppt2">Provider Name:Jobse Lebron Perez, 11/26/2024 08:30:00 AM, 320 W FLETCHER AVE, STE 101, TAMPA, FL, 33612-3400, 813-374-9266</td></tr></tbody></table></div><h3><a name="id9" href="#toc">Procedure Notes</a></h3><div><ul><li><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th></tr></thead><tbody><tr><td>Sunoh.ai</td><td>Sunoh.ai</td><td colspan="2">The patient consented for use of ambient listening software prior to the start of visit. The use of this software permits real-time transcription between the patient and the provider to be stored for no more than seven (7) days from the date of recording. I explained the inherent limits to using this service including potential risks associated with the privacy and security of the technology. I personally performed the services as described in this documentation as scribed by Sunoh.ai in my presence and it is both accurate and complete</td></tr></tbody></table><br/></li></ul></div><h3><a name="id10" href="#toc">Progress Notes</a></h3><div><ul><li><table width="99%" border="0" cellspacing="0" cellpadding="0"><thead><tr><td><content>RIFE, Martin <span class="bold">DOB:</span> 03/12/1961 (63 yo M) <span class="bold">Acc No.</span> 233694 <span class="bold">DOS:</span> 08/26/2024</content></td></tr></thead><tbody><tr><td>UNLOCKED PROGRESS NOTE</td></tr><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td align="right" colspan="2"><span class="bold"/></td></tr><tr><td align="left"><span class="bold">Patient: </span>RIFE, Martin<br/><span class="bold">Account Number: </span>233694</td><td align="right"><span class="bold">Provider: </span>Jobse Lebron Perez, MD</td></tr><tr><td align="left"/></tr><tr><td align="left"><span class="bold">DOB: </span>03/12/1961<span class="bold">   Age: </span>63 Y<span class="bold">   Sex: </span>Male</td><td align="right"><span class="bold">Date: </span>08/26/2024</td></tr><tr><td><span class="bold">Phone: </span>813-638-2969</td></tr><tr><td colspan="2"><span class="bold">Address: </span>10938 N 29TH ST, TAMPA, FL-33612-3850</td></tr></tbody></table></li></ul><br/><content><span class="bold">Subjective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Chief Complaints:</span></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td>   1. EOV with labs. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">ROS:</span> <br/>   Cardiovascular: <br/>Chest pain -&gt; denies<br/>  Difficulty laying flat -&gt; denies<br/>  Orthopnea -&gt; denies<br/>  Palpitations -&gt; denies<br/>  <br/><br/>Endocrine: <br/>Weight Gain -&gt; denies<br/>  Cold intolerance -&gt; denies<br/>  Excessive thirst -&gt; denies<br/>  Weight loss -&gt; denies<br/>  <br/><br/>ENT: <br/>Runny Nose -&gt; denies<br/>  Decreased hearing -&gt; denies<br/>  Nosebleed -&gt; denies<br/>  Ringing in the ears -&gt; denies<br/>  Sinus pain -&gt; denies<br/>  Sore throat -&gt; denies<br/>  Swollen glands -&gt; denies<br/>  <br/><br/>Gastrointestinal: <br/>Abdominal pain -&gt; denies<br/>  Change in bowel habits -&gt; denies<br/>  Constipation -&gt; denies<br/>  Diarrhea -&gt; denies<br/>  Difficulty swallowing -&gt; denies<br/>  Heartburn -&gt; denies<br/>  Nausea -&gt; denies<br/>  Vomiting -&gt; denies<br/>  <br/><br/>General/Constitutional: <br/>Change in appetite -&gt; denies<br/>  Chills -&gt; denies<br/>  Fatigue -&gt; denies<br/>  <br/><br/>Genitourinary: <br/>Blood in urine -&gt; denies<br/>  Difficulty urinating -&gt; denies<br/>  Frequent urination -&gt; denies<br/>  Painful urination -&gt; denies<br/>  Urinary retention -&gt; denies<br/>  <br/><br/>Hematology: <br/>Bleeding disorder -&gt; denies<br/>  <br/><br/>Musculoskeletal: <br/>Back pain -&gt;  admits<br/>  Knee Pain -&gt; , denies<br/>  Joint stiffness -&gt; denies<br/>  Muscle aches -&gt;  admits<br/>  Pain in shoulder(s) -&gt; denies<br/>  Swollen joints -&gt; denies<br/>  <br/><br/>Neurologic: <br/>Dizziness/Lightheadedness -&gt; denies<br/>  Fainting -&gt; denies<br/>  Gait abnormality -&gt; denies<br/>  Headache -&gt; denies<br/>  Memory loss -&gt; denies<br/>  Seizures -&gt; denies<br/>  Tingling/Numbness -&gt; denies<br/>  Tremor -&gt; denies<br/>  <br/><br/>Ophthalmologic: <br/>Blurred vision -&gt; denies<br/>  Discharge -&gt; denies<br/>  Itching and redness -&gt; denies<br/>  <br/><br/>Peripheral Vascular: <br/>Vericose Veins -&gt; denies<br/>  Cold extremities -&gt; denies<br/>  Pain/cramping in legs after exertion -&gt; denies<br/>  Painful extremities -&gt; denies<br/>  Ulceration of feet -&gt; denies<br/>  <br/><br/>Podiatric: <br/>Ankle pain -&gt; denies<br/>  Ball of foot pain -&gt; denies<br/>  Foot pain -&gt; denies<br/>  Sole pain -&gt; denies<br/>  <br/><br/>Psychiatric: <br/>Homicidal thoughts -&gt; denies<br/>  Anxiety -&gt; admits, controlled by medications<br/>  Auditory/visual hallucinations -&gt; denies<br/>  Delusions -&gt; denies<br/>  Depressed mood -&gt; admits,controlled with medication<br/>  Difficulty sleeping -&gt; admits  but sleeping better<br/>  Loss of appetite -&gt; denies<br/>  Stressors -&gt; denies<br/>  Suicidal thoughts -&gt; denies<br/>  <br/><br/>Respiratory: <br/>Cough -&gt; denies<br/>  Hemoptysis -&gt; denies<br/>  Pain with inspiration -&gt; denies<br/>  Shortness of breath with exertion -&gt; denies<br/>  Sputum production -&gt; denies<br/>  Wheezing -&gt; denies<br/>  <br/><br/>Skin: <br/>Hair loss -&gt; denies<br/>  Dry skin -&gt; denies<br/>  Eczema -&gt; denies<br/>  Itching -&gt; denies<br/>  Atypical Mole(s) -&gt; denies<br/>  Rash -&gt; denies.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medical History:</span> Osteoarthrosis, unspecified whether generalized or localized, unspecified site, Bipolar disorder, unspecified, Schizophreniform disorder, chronic, pschy  dr suzane bhat at MLK , Painmanagment dr kamat neurology, Previuos PCP Dr Kamat,White Bath at Tampa Family Fl Ave, Pt found us in Optimun Book, Adjustment disorder, unspecified, Chronic viral hepatitis C, Thrombocytosis, Colonoscopy 6/ 2013 wnl ptn does not remember the doctors name, Flu shot given 10/24/18, Adjustment disorder, unspecified type, Hypertriglyceridemia, Osteoarthritis of spine with radiculopathy, cervical region, Lumbar spondylosis, Disc disease, degenerative, cervical, Bulging lumbar disc, Other intervertebral disc degeneration, lumbosacral region, Radiculopathy, lumbar region, Elevated liver enzymes.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Surgical History:</span> Lt Knee at TGH 2014, Lt hand at TGH 2014. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Family History:</span> Father: deceased 68 yrs, alcohol abuse. Mother: deceased 62 yrs, lung cancer. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Social History:</span> <br/>   <span class="Underline">Migrated Social History:</span> <br/>       Drugs/Alcohol: (Alcohol Screen):Did you have a drink containing alcohol in the past year?: Yes, How often did you have a drink containing alcohol in the past year?: Monthly or less (1 point), How many drinks did you have on a typical day when you were drinking in the past year?: 1 or 2 drinks (0 point), How often did you have 6 or more drinks on one occasion in the past year?: Never (0 point), Points: 1, Interpretation: Negative(Drugs):Have you used drugs other than those for medical reasons in the past 12 months? No. <br/>      Miscellaneous: (Caffeine:):more than 4 cups per day(Children:):aware of safety issues(Community involvements:):none(Domestic violence:):none(Exercise:):occasional(Home smoke detector use:):smoke detectors(Housing:):owning(Legal problems:):none(Living with:):alone(Marital status:):divorced(Natural support system:):none(Working):retired. <br/>      Sexual History: (Sexual History):Had sex in the past 12 months (vaginal, oral, or anal)?: No, Have you ever had a Sexually transmitted disease?: No. <br/>      Tobacco Use: (Tobacco Use/Smoking):Are you a: former smoker , How long it has been since you last smoked?: 3-6 months, Additional Findings: Tobacco User: Heavy cigarette smoker (20-39 cigs/day), Additional Findings: Tobacco Non-User: Ex-heavy cigarette smoker (20-30/day). </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medications:</span> Taking Albuterol Sulfate HFA 108 (90 Base) MCG/ACT Aerosol Solution INHALE 2 PUFFS BY MOUTH EVERY FOUR HOURS   , Taking Diclofenac Sodium 75 MG Tablet Delayed Release 1 tablet Orally Twice a day , Taking Lisinopril 5 MG Tablet 1 tablet Orally Once a day , Taking risperiDONE 4 MG Tablet TAKE 1 TABLET BY MOUTH TWICE A DAY Orally twice a day , Taking Sertraline HCl 100 MG Tablet 1 tablet Orally Twice a day , Taking Atorvastatin Calcium 80 MG Tablet 1 tablet Orally Once a night , Taking Banophen 50 MG Capsule TAKE 2 CAPSULES BY MOUTH DAILY   , Taking Fenofibrate 160 MG Tablet TAKE ONE TABLET BY MOUTH DAILY WITH FOOD Orally Once a day , Taking Gabapentin 300 MG Capsule take one capsule by mouth 3 times daily Orally every 8 hrs for as needed , Notes to Pharmacist: PM, Taking Mirtazapine 30 MG Tablet 1 tablet at bedtime Orally Once a day , Taking Naloxone HCl 4 MG/0.1ML Liquid Naloxone intranasal Nasally as needed , Discontinued Baclofen 20 MG Tablet TAKE 1 TABLET BY MOUTH TWICE A DAY WITH FOOD OR MILK   , Discontinued Niacin ER 1000 MG Tablet Extended Release 1 tablet with food Orally Once a day , Unknown Aspirin 325 MG Tablet 1 tablet Orally Once a day , Unknown oxyCODONE-Acetaminophen 5-325 MG Tablet 1 tablet as needed Orally every 6 hrs , Notes to Pharmacist: PM, Medication List reviewed and reconciled with the patient</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Allergies:</span> N.K.D.A.</td></tr></tbody></table></li></ul><br/><content><span class="bold">Objective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Vitals:</span> Ht: 72 in, Wt: <span class="bold">222</span> lbs, Wt-kg: 100.7 kg, BMI: <span class="bold">30.11</span> Index, BP: <span class="bold">112/74</span> mm Hg, HR: <span class="bold">68</span> /min, Temp: <span class="bold">97.9</span> F, RR: <span class="bold">16</span> /min, Oxygen sat %: <span class="bold">97</span> %, Body Surface Area: 2.26.<br/></td></tr></tbody></table></li></ul><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><span class="bold">   Past Orders:</span></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Hemoglobin A1c-001453</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">08/19/2024</td><td align="left">04/08/2024</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Collection Time</td><td align="left"/><td align="left">12:45 PM</td><td align="left"/><td align="left"/></tr><tr><td align="left">Order Date</td><td align="left">04/15/2024</td><td align="left">10/17/2023</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Hemoglobin A1c</td><td class="bold" align="left">6.2    H<br/>(Ref Range: 4.8-5.6 %)</td><td class="bold" align="left">6.2    H<br/>(Ref Range: 4.8-5.6 %)</td><td class="bold" align="left">6.0    H<br/>(Ref Range: 4.8-5.6 %)</td><td class="bold" align="left">5.9    H<br/>(Ref Range: 4.8-5.6 %)</td></tr><tr><td align="left">Notes:</td><td align="left"/><td align="left">Brunk, Ronald 4/10/2024 01:34:40 PM EDT &gt;reviewed</td><td align="left">Lebron Perez, Jobse 10/16/2023 12:52:31 PM &gt;reviewed</td><td align="left">Lebron Perez, Jobse 7/20/2023 09:52:42 AM &gt;reviewed</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:CBC With Differential/Platelet-005009</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">08/19/2024</td><td align="left">04/08/2024</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Collection Time</td><td align="left"/><td align="left">12:45 PM</td><td align="left"/><td align="left"/></tr><tr><td align="left">Order Date</td><td align="left">04/15/2024</td><td align="left">10/17/2023</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">WBC</td><td align="left">6.2<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td><td align="left">6.6<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td><td align="left">8.3<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td><td align="left">7.7<br/>(Ref Range: 3.4-10.8 x10E3/uL)</td></tr><tr><td align="left">RBC</td><td align="left">4.59<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td><td align="left">4.68<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td><td align="left">4.86<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td><td align="left">4.95<br/>(Ref Range: 4.14-5.80 x10E6/uL)</td></tr><tr><td align="left">Hemoglobin</td><td align="left">13.9<br/>(Ref Range: 13.0-17.7 g/dL)</td><td align="left">13.8<br/>(Ref Range: 13.0-17.7 g/dL)</td><td align="left">14.5<br/>(Ref Range: 13.0-17.7 g/dL)</td><td align="left">15.0<br/>(Ref Range: 13.0-17.7 g/dL)</td></tr><tr><td align="left">Hematocrit</td><td align="left">42.1<br/>(Ref Range: 37.5-51.0 %)</td><td align="left">42.2<br/>(Ref Range: 37.5-51.0 %)</td><td align="left">44.7<br/>(Ref Range: 37.5-51.0 %)</td><td align="left">44.7<br/>(Ref Range: 37.5-51.0 %)</td></tr><tr><td align="left">MCV</td><td align="left">92<br/>(Ref Range: 79-97 fL)</td><td align="left">90<br/>(Ref Range: 79-97 fL)</td><td align="left">92<br/>(Ref Range: 79-97 fL)</td><td align="left">90<br/>(Ref Range: 79-97 fL)</td></tr><tr><td align="left">MCH</td><td align="left">30.3<br/>(Ref Range: 26.6-33.0 pg)</td><td align="left">29.5<br/>(Ref Range: 26.6-33.0 pg)</td><td align="left">29.8<br/>(Ref Range: 26.6-33.0 pg)</td><td align="left">30.3<br/>(Ref Range: 26.6-33.0 pg)</td></tr><tr><td align="left">MCHC</td><td align="left">33.0<br/>(Ref Range: 31.5-35.7 g/dL)</td><td align="left">32.7<br/>(Ref Range: 31.5-35.7 g/dL)</td><td align="left">32.4<br/>(Ref Range: 31.5-35.7 g/dL)</td><td align="left">33.6<br/>(Ref Range: 31.5-35.7 g/dL)</td></tr><tr><td align="left">RDW</td><td align="left">13.9<br/>(Ref Range: 11.6-15.4 %)</td><td align="left">13.1<br/>(Ref Range: 11.6-15.4 %)</td><td align="left">13.8<br/>(Ref Range: 11.6-15.4 %)</td><td align="left">14.0<br/>(Ref Range: 11.6-15.4 %)</td></tr><tr><td align="left">Platelets</td><td align="left">357<br/>(Ref Range: 150-450 x10E3/uL)</td><td align="left">356<br/>(Ref Range: 150-450 x10E3/uL)</td><td align="left">383<br/>(Ref Range: 150-450 x10E3/uL)</td><td align="left">386<br/>(Ref Range: 150-450 x10E3/uL)</td></tr><tr><td align="left">Neutrophils</td><td align="left">61<br/>(Ref Range: Not Estab. %)</td><td align="left">57<br/>(Ref Range: Not Estab. %)</td><td align="left">67<br/>(Ref Range: Not Estab. %)</td><td align="left">66<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Lymphs</td><td align="left">25<br/>(Ref Range: Not Estab. %)</td><td align="left">30<br/>(Ref Range: Not Estab. %)</td><td align="left">23<br/>(Ref Range: Not Estab. %)</td><td align="left">25<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Monocytes</td><td align="left">8<br/>(Ref Range: Not Estab. %)</td><td align="left">8<br/>(Ref Range: Not Estab. %)</td><td align="left">7<br/>(Ref Range: Not Estab. %)</td><td align="left">6<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Eos</td><td align="left">4<br/>(Ref Range: Not Estab. %)</td><td align="left">3<br/>(Ref Range: Not Estab. %)</td><td align="left">2<br/>(Ref Range: Not Estab. %)</td><td align="left">2<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Basos</td><td align="left">2<br/>(Ref Range: Not Estab. %)</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Neutrophils (Absolute)</td><td align="left">3.8<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td><td align="left">3.8<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td><td align="left">5.6<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td><td align="left">5.0<br/>(Ref Range: 1.4-7.0 x10E3/uL)</td></tr><tr><td align="left">Lymphs (Absolute)</td><td align="left">1.5<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td><td align="left">2.0<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td><td align="left">1.9<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td><td align="left">1.9<br/>(Ref Range: 0.7-3.1 x10E3/uL)</td></tr><tr><td align="left">Monocytes(Absolute)</td><td align="left">0.5<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td><td align="left">0.5<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td><td align="left">0.6<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td><td align="left">0.4<br/>(Ref Range: 0.1-0.9 x10E3/uL)</td></tr><tr><td align="left">Eos (Absolute)</td><td align="left">0.2<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td><td align="left">0.2<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td><td align="left">0.2<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td><td align="left">0.2<br/>(Ref Range: 0.0-0.4 x10E3/uL)</td></tr><tr><td align="left">Baso (Absolute)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td><td align="left">0.1<br/>(Ref Range: 0.0-0.2 x10E3/uL)</td></tr><tr><td align="left">Immature Granulocytes</td><td align="left">0<br/>(Ref Range: Not Estab. %)</td><td align="left">1<br/>(Ref Range: Not Estab. %)</td><td align="left">0<br/>(Ref Range: Not Estab. %)</td><td align="left">0<br/>(Ref Range: Not Estab. %)</td></tr><tr><td align="left">Immature Grans (Abs)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td><td align="left">0.0<br/>(Ref Range: 0.0-0.1 x10E3/uL)</td></tr><tr><td align="left">Notes:</td><td align="left"/><td align="left">Brunk, Ronald 4/10/2024 01:34:40 PM EDT &gt;reviewed</td><td align="left">Lebron Perez, Jobse 10/16/2023 12:52:31 PM &gt;reviewed</td><td align="left">Lebron Perez, Jobse 7/20/2023 09:52:42 AM &gt;reviewed</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Lipid Panel-303756</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">08/19/2024</td><td align="left">04/08/2024</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Collection Time</td><td align="left"/><td align="left">12:45 PM</td><td align="left"/><td align="left"/></tr><tr><td align="left">Order Date</td><td align="left">04/15/2024</td><td align="left">10/17/2023</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Cholesterol, Total</td><td align="left">140<br/>(Ref Range: 100-199 mg/dL)</td><td align="left">159<br/>(Ref Range: 100-199 mg/dL)</td><td align="left">158<br/>(Ref Range: 100-199 mg/dL)</td><td align="left">151<br/>(Ref Range: 100-199 mg/dL)</td></tr><tr><td align="left">Triglycerides</td><td class="bold" align="left">169    H<br/>(Ref Range: 0-149 mg/dL)</td><td class="bold" align="left">251    H<br/>(Ref Range: 0-149 mg/dL)</td><td class="bold" align="left">201    H<br/>(Ref Range: 0-149 mg/dL)</td><td class="bold" align="left">229    H<br/>(Ref Range: 0-149 mg/dL)</td></tr><tr><td align="left">HDL Cholesterol</td><td class="bold" align="left">37    L<br/>(Ref Range: &gt;39 mg/dL)</td><td class="bold" align="left">35    L<br/>(Ref Range: &gt;39 mg/dL)</td><td class="bold" align="left">39    L<br/>(Ref Range: &gt;39 mg/dL)</td><td class="bold" align="left">34    L<br/>(Ref Range: &gt;39 mg/dL)</td></tr><tr><td align="left">VLDL Cholesterol Cal</td><td align="left">29<br/>(Ref Range: 5-40 mg/dL)</td><td class="bold" align="left">42    H<br/>(Ref Range: 5-40 mg/dL)</td><td align="left">34<br/>(Ref Range: 5-40 mg/dL)</td><td align="left">38<br/>(Ref Range: 5-40 mg/dL)</td></tr><tr><td align="left">LDL Chol Calc (NIH)</td><td align="left">74<br/>(Ref Range: 0-99 mg/dL)</td><td align="left">82<br/>(Ref Range: 0-99 mg/dL)</td><td align="left">85<br/>(Ref Range: 0-99 mg/dL)</td><td align="left">79<br/>(Ref Range: 0-99 mg/dL)</td></tr><tr><td align="left">Notes:</td><td align="left"/><td align="left">Brunk, Ronald 4/10/2024 01:34:40 PM EDT &gt;reviewed</td><td align="left">Lebron Perez, Jobse 10/16/2023 12:52:31 PM &gt;reviewed</td><td align="left">Lebron Perez, Jobse 7/20/2023 09:52:42 AM &gt;reviewed</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:CMP14+eGFR-334943</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">08/19/2024</td><td align="left">04/08/2024</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Collection Time</td><td align="left"/><td align="left">12:45 PM</td><td align="left"/><td align="left"/></tr><tr><td align="left">Order Date</td><td align="left">04/15/2024</td><td align="left">10/17/2023</td><td align="left">10/11/2023</td><td align="left">07/19/2023</td></tr><tr><td align="left">Glucose</td><td class="bold" align="left">106    H<br/>(Ref Range: 70-99 mg/dL)</td><td class="bold" align="left">122    H<br/>(Ref Range: 70-99 mg/dL)</td><td class="bold" align="left">109    H<br/>(Ref Range: 70-99 mg/dL)</td><td class="bold" align="left">151    H<br/>(Ref Range: 70-99 mg/dL)</td></tr><tr><td align="left">BUN</td><td align="left">9<br/>(Ref Range: 8-27 mg/dL)</td><td align="left">8<br/>(Ref Range: 8-27 mg/dL)</td><td align="left">13<br/>(Ref Range: 8-27 mg/dL)</td><td align="left">11<br/>(Ref Range: 8-27 mg/dL)</td></tr><tr><td align="left">Creatinine</td><td align="left">1.01<br/>(Ref Range: 0.76-1.27 mg/dL)</td><td align="left">1.04<br/>(Ref Range: 0.76-1.27 mg/dL)</td><td align="left">1.16<br/>(Ref Range: 0.76-1.27 mg/dL)</td><td align="left">1.27<br/>(Ref Range: 0.76-1.27 mg/dL)</td></tr><tr><td align="left">eGFR</td><td align="left">84<br/>(Ref Range: &gt;59 mL/min/1.73)</td><td align="left">81<br/>(Ref Range: &gt;59 mL/min/1.73)</td><td align="left">71<br/>(Ref Range: &gt;59 mL/min/1.73)</td><td align="left">64<br/>(Ref Range: &gt;59 mL/min/1.73)</td></tr><tr><td align="left">BUN/Creatinine Ratio</td><td class="bold" align="left">9    L<br/>(Ref Range: 10-24)</td><td class="bold" align="left">8    L<br/>(Ref Range: 10-24)</td><td align="left">11<br/>(Ref Range: 10-24)</td><td class="bold" align="left">9    L<br/>(Ref Range: 10-24)</td></tr><tr><td align="left">Sodium</td><td align="left">138<br/>(Ref Range: 134-144 mmol/L)</td><td align="left">136<br/>(Ref Range: 134-144 mmol/L)</td><td align="left">137<br/>(Ref Range: 134-144 mmol/L)</td><td align="left">141<br/>(Ref Range: 134-144 mmol/L)</td></tr><tr><td align="left">Potassium</td><td align="left">4.4<br/>(Ref Range: 3.5-5.2 mmol/L)</td><td align="left">4.7<br/>(Ref Range: 3.5-5.2 mmol/L)</td><td class="bold" align="left">5.6    H<br/>(Ref Range: 3.5-5.2 mmol/L)</td><td align="left">4.9<br/>(Ref Range: 3.5-5.2 mmol/L)</td></tr><tr><td align="left">Chloride</td><td align="left">100<br/>(Ref Range: 96-106 mmol/L)</td><td align="left">96<br/>(Ref Range: 96-106 mmol/L)</td><td align="left">99<br/>(Ref Range: 96-106 mmol/L)</td><td align="left">98<br/>(Ref Range: 96-106 mmol/L)</td></tr><tr><td align="left">Carbon Dioxide, Total</td><td align="left">25<br/>(Ref Range: 20-29 mmol/L)</td><td align="left">25<br/>(Ref Range: 20-29 mmol/L)</td><td align="left">25<br/>(Ref Range: 20-29 mmol/L)</td><td align="left">25<br/>(Ref Range: 20-29 mmol/L)</td></tr><tr><td align="left">Calcium</td><td align="left">9.7<br/>(Ref Range: 8.6-10.2 mg/dL)</td><td align="left">10.0<br/>(Ref Range: 8.6-10.2 mg/dL)</td><td class="bold" align="left">10.3    H<br/>(Ref Range: 8.6-10.2 mg/dL)</td><td class="bold" align="left">10.4    H<br/>(Ref Range: 8.6-10.2 mg/dL)</td></tr><tr><td align="left">Protein, Total</td><td align="left">6.7<br/>(Ref Range: 6.0-8.5 g/dL)</td><td align="left">6.5<br/>(Ref Range: 6.0-8.5 g/dL)</td><td align="left">6.7<br/>(Ref Range: 6.0-8.5 g/dL)</td><td align="left">6.6<br/>(Ref Range: 6.0-8.5 g/dL)</td></tr><tr><td align="left">Albumin</td><td align="left">4.7<br/>(Ref Range: 3.9-4.9 g/dL)</td><td class="bold" align="left">5.0    H<br/>(Ref Range: 3.9-4.9 g/dL)</td><td align="left">4.8<br/>(Ref Range: 3.9-4.9 g/dL)</td><td align="left">4.9<br/>(Ref Range: 3.9-4.9 g/dL)</td></tr><tr><td align="left">Globulin, Total</td><td align="left">2.0<br/>(Ref Range: 1.5-4.5 g/dL)</td><td align="left">1.5<br/>(Ref Range: 1.5-4.5 g/dL)</td><td align="left">1.9<br/>(Ref Range: 1.5-4.5 g/dL)</td><td align="left">1.7<br/>(Ref Range: 1.5-4.5 g/dL)</td></tr><tr><td align="left">A/G Ratio</td><td align="left">NR<br/></td><td class="bold" align="left">3.3    H<br/>(Ref Range: 1.2-2.2)</td><td class="bold" align="left">2.5    H<br/>(Ref Range: 1.2-2.2)</td><td class="bold" align="left">2.9    H<br/>(Ref Range: 1.2-2.2)</td></tr><tr><td align="left">Bilirubin, Total</td><td align="left">0.2<br/>(Ref Range: 0.0-1.2 mg/dL)</td><td align="left">&lt;0.2<br/>(Ref Range: 0.0-1.2 mg/dL)</td><td align="left">0.4<br/>(Ref Range: 0.0-1.2 mg/dL)</td><td align="left">0.3<br/>(Ref Range: 0.0-1.2 mg/dL)</td></tr><tr><td align="left">Alkaline Phosphatase</td><td align="left">44<br/>(Ref Range: 44-121 IU/L)</td><td align="left">45<br/>(Ref Range: 44-121 IU/L)</td><td align="left">44<br/>(Ref Range: 44-121 IU/L)</td><td class="bold" align="left">43    L<br/>(Ref Range: 44-121 IU/L)</td></tr><tr><td align="left">AST (SGOT)</td><td align="left">19<br/>(Ref Range: 0-40 IU/L)</td><td align="left">19<br/>(Ref Range: 0-40 IU/L)</td><td align="left">28<br/>(Ref Range: 0-40 IU/L)</td><td align="left">21<br/>(Ref Range: 0-40 IU/L)</td></tr><tr><td align="left">ALT (SGPT)</td><td align="left">18<br/>(Ref Range: 0-44 IU/L)</td><td align="left">24<br/>(Ref Range: 0-44 IU/L)</td><td align="left">14<br/>(Ref Range: 0-44 IU/L)</td><td align="left">16<br/>(Ref Range: 0-44 IU/L)</td></tr><tr><td align="left">Notes:</td><td align="left"/><td align="left">Brunk, Ronald 4/10/2024 01:34:40 PM EDT &gt;reviewed</td><td align="left">Lebron Perez, Jobse 10/16/2023 12:52:31 PM &gt;reviewed</td><td align="left">Lebron Perez, Jobse 7/20/2023 09:52:42 AM &gt;reviewed</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr><tr><td colspan="4"><ul><li><table width="100%"><tbody><tr><td><ul><li><table border="1"><tbody><tr><td colspan="4"><content class="Underline"><span class="bold">Lab:Occult Blood, Fecal, IA-182949</span></content></td></tr></tbody></table></li></ul><ul><li><table frame="void" rules="rows" cellpadding="0" cellspacing="0" border="1" width="100%"><tbody><tr><td align="left">Collection Date</td><td align="left">04/23/2024</td><td align="left">10/17/2023</td></tr><tr><td align="left">Order Date</td><td align="left">04/23/2024</td><td align="left">10/17/2023</td></tr><tr><td align="left">Occult Blood, Fecal, IA</td><td align="left">Negative<br/>(Ref Range: Negative)</td><td class="bold" align="left">Positive    A<br/>(Ref Range: Negative)</td></tr><tr><td align="left">Notes:</td><td align="left"/><td align="left">Cartagena Galindo, Elizabeth 10/20/2023 03:16:04 PM &gt; noted</td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content class="bold">Examination: <br/></content>   <span class="Underline">Migrated Examinations:</span><br/>   General Examination:<br/>GENERAL APPEARANCE: -&gt; in no acute distress, well developed, well nourished<br/>  HEAD: -&gt; normocephalic, atraumatic<br/>  EYES: -&gt; pupils equal, round, reactive to light and accommodation<br/>  EARS: -&gt; normal<br/>  NOSE: -&gt; nares patent, no lesions<br/>  ORAL CAVITY: -&gt; mucosa moist<br/>  THROAT: -&gt; clear<br/>  NECK/THYROID: -&gt; neck supple, full range of motion, no cervical lymphadenopathy<br/>  LYMPH NODES: -&gt; no lymphadenopathy<br/>  SKIN: -&gt; no suspicious lesions, warm and dry<br/>  HEART: -&gt; no murmurs, regular rate and rhythm, S1, S2 normal<br/>  LUNGS: -&gt; To auscultation bilaterally expiratory wheezes<br/>  CHEST: -&gt; no costochondral tenderness<br/>  ABDOMEN: -&gt; normal, bowel sounds present, soft, nontender, nondistended<br/>  BACK: -&gt; no costovertebral angle tenderness, spine nontender to palpation<br/>  MUSCULOSKELETAL: -&gt; neck, lumbar paraspinal muscle tenderness to examination<br/>  EXTREMITIES: -&gt; no clubbing, cyanosis, or edema. Loss of hair and darker skin<br/>  PERIPHERAL PULSES: -&gt; normal<br/>  NEUROLOGIC: -&gt; nonfocal, motor strength normal upper and lower extremities, sensory exam intact.<br/></td></tr><tr><td/></tr></tbody></table></li></ul><br/><content><span class="bold">Assessment:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Assessment: </span></td></tr><tr><td/></tr><tr><td>1. Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease - I12.9 (Primary)   <content><span class="bold">Specify : </span>CKD stage 2</content>   <content><span class="bold">Notes : </span>CKD stage 2</content>   2. Chronic viral hepatitis C - B18.2   3. Mixed hyperlipidemia - E78.2   4. Hypercalcemia - E83.52   5. Smoker - F17.200   6. Other specified types of schizophrenia, chronic condition - F20.89   7. Bipolar 1 disorder, depressed - F31.9   8. Anxiety state - F41.1   9. Primary insomnia - F51.01   10. Chronic pain syndrome - G89.4   11. PVD (peripheral vascular disease) - I73.9   12. Chronic airway obstruction, not elsewhere classified - J44.9   13. Primary osteoarthritis involving multiple joints - M15.0   14. Primary osteoarthritis of left knee - M17.12   15. Cervical radiculopathy due to degenerative joint disease of spine - M47.22   16. Spondylosis without myelopathy or radiculopathy, lumbosacral region - M47.817   17. Displacement of lumbar intervertebral disc - M51.26   <content><span class="bold">Notes : </span>Florida PM notes dated 07/12/2022</content>   18. Lumbago with sciatica, right side - M54.41   19. Lumbago with sciatica, left side - M54.42   20. Muscle spasm - M62.838   21. CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min - N18.2   <content><span class="bold">Notes : </span>GFR 67</content>   22. Pre-diabetes - R73.03   23. Other long term (current) drug therapy - Z79.899   24. Disc disease, degenerative, cervical - M50.30   25. Opiate dependence - F11.20   26. Microalbuminuria - R80.9   </td></tr></tbody></table></li></ul><br/><content><span class="bold">Plan:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Treatment:</span></td></tr><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">1. Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease</span> <br/>Refill Lisinopril Tablet, 5 MG, 1 tablet, Orally, Once a day, 90 days, 90 Tablet, Refills 3.  <br/>Notes: Low Na diet  </td></tr><tr><td/></tr><tr><td><span class="bold">2. Chronic viral hepatitis C</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">3. Mixed hyperlipidemia</span> <br/>Continue Niacin ER Tablet Extended Release, 1000 MG, 1 tablet with food, Orally, Once a day; Refill Atorvastatin Calcium Tablet, 80 MG, 1 tablet, Orally, Once a night, 90 days, 90, Refills 3; Refill Fenofibrate Tablet, 160 MG, TAKE ONE TABLET BY MOUTH DAILY WITH FOOD, Orally, Once a day, 90 days, 90, Refills 1.  <br/>Notes: Low fat diet  </td></tr><tr><td/></tr><tr><td><span class="bold">4. Hypercalcemia</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">5. Smoker</span> <br/>Notes: Patient counseled and Educated on dangers of tobacco use and urged him to decrease smoking and then to quit; patient not ready to quit yet  </td></tr><tr><td/></tr><tr><td><span class="bold">6. Other specified types of schizophrenia, chronic condition</span> <br/>Continue risperiDONE Tablet, 4 MG, 1 tablet, Orally, Twice a day, 90 days, 180 Tablet, Refills 1.  <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">7. Bipolar 1 disorder, depressed</span> <br/>Continue Sertraline HCl Tablet, 100 MG, TAKE ONE TABLET BY MOUTH TWICE A DAY, Orally, Twice a day, 90 days, 180, Refills 0.  <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">8. Anxiety state</span> <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">9. Primary insomnia</span> <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">10. Chronic pain syndrome</span> <br/>Continue oxyCODONE-Acetaminophen Tablet, 5-325 MG, 1 tablet as needed, Orally, every 6 hrs, Notes to Pharmacist: PM.  <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">11. PVD (peripheral vascular disease)</span> <br/>Notes: ASA  </td></tr><tr><td/></tr><tr><td><span class="bold">12. Chronic airway obstruction, not elsewhere classified</span> <br/>Continue Albuterol Sulfate HFA Aerosol Solution, 108 (90 Base) MCG/ACT, INHALE 2 PUFFS BY MOUTH EVERY FOUR HOURS, every 4 hrs.  <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">13. Primary osteoarthritis involving multiple joints</span> <br/>Continue Gabapentin Capsule, 300 MG, take one capsule by mouth 3 times daily, Orally, every 8 hrs for as needed, Notes to Pharmacist: PM.  <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">14. Primary osteoarthritis of left knee</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">15. Cervical radiculopathy due to degenerative joint disease of spine</span> <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">16. Spondylosis without myelopathy or radiculopathy, lumbosacral region</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">17. Displacement of lumbar intervertebral disc</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">18. Lumbago with sciatica, right side</span> <br/>Notes: Continue current treatment  </td></tr><tr><td/></tr><tr><td><span class="bold">19. Lumbago with sciatica, left side</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">20. Muscle spasm</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">21. CKD (chronic kidney disease) stage 2, GFR 60-89 ml/min</span> <br/>Notes: Drink plenty of water  </td></tr><tr><td/></tr><tr><td><span class="bold">22. Pre-diabetes</span> <br/>Notes: diabetic diet and exercise  </td></tr><tr><td/></tr><tr><td><span class="bold">23. Other long term (current) drug therapy</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">24. Disc disease, degenerative, cervical</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr><tr><td><span class="bold">25. Opiate dependence</span> <br/>Continue Naloxone HCl Liquid, 4 MG/0.1ML, Naloxone intranasal, Nasally, as needed.  <br/>Notes: 1) Drug has been taken for lager amount or over longer period than was intended2) Persistent desire or unsuccessful efforts to cut down or control use3) Craving or strong desire or urge to use the drug4) continued use despite knowledge of having a persistent or recurrent physical or phychological problem that is likely caused or exacerbated by the drug.  </td></tr><tr><td/></tr><tr><td><span class="bold">26. Microalbuminuria</span> <br/>Notes: Monitor for changes  </td></tr><tr><td/></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Procedures:</span> <br/>   <span class="Underline">Sunoh.ai</span>: <br/>      Sunoh.ai The patient consented for use of ambient listening software prior to the start of visit. The use of this software permits real-time transcription between the patient and the provider to be stored for no more than seven (7) days from the date of recording. I explained the inherent limits to using this service including potential risks associated with the privacy and security of the technology. I personally performed the services as described in this documentation as scribed by Sunoh.ai in my presence and it is both accurate and complete.   <br/>      </td></tr><tr><td/></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Procedure Codes:</span> 3074F SYST BP LT 130 MM HG, 3078F DIAST BP &lt; 80 MM HG, G8417 BMI &gt;=30 CALCUATE W/FOLLOWUP, G8427 DOC MEDS VERIFIED W/PT OR RE</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Preventive Medicine:</span> <br/>  <br/>   Counseling: Patient Education - Patient education materials given: Yes;<br/>  Body Mass Index - BMI management provided Yes;<br/>  ;<br/>.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Follow Up:</span> 3 Months,on Regular Scheduled OV (Reason: Follow-up of chronic conditions)</td></tr></tbody></table></li></ul><ul><li/></ul><br/><content><span class="bold">Billing  Information:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content><span class="bold">Visit Code:</span></content> <br/>99214 Office Visit, Est Pt., Level 4.  </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content><span class="bold">Procedure Codes:</span></content> <br/>3074F SYST BP LT 130 MM HG. <br/>3078F DIAST BP &lt; 80 MM HG. <br/>G8417 BMI &gt;=30 CALCUATE W/FOLLOWUP. <br/>G8427 DOC MEDS VERIFIED W/PT OR RE. </td></tr></tbody></table></li></ul><br/><tr><td valign="top"><span class="bold">Care Plan Details</span><ul><li><table cellpadding="1" cellspacing="0" border="1"><tbody/></table></li></ul></td></tr><ul><li><table width="100%" border="0"><tbody><tr><td/></tr><tr><td valign="top"/></tr><tr><td/></tr><tr><td/></tr><tr><td valign="top">Electronic signature of Jobse Lebron Perez , MD, ACN765  on 08/29/2024 at 04:02 PM EDT</td></tr><tr><td valign="top">Sign off status: Pending</td></tr><tr><td/></tr></tbody></table></li></ul><span class="content_span"/></td></tr></tbody><tbody><tr><td><br/><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td align="left"><span class="bold">Provider:</span> Jobse Lebron Perez, MD</td><td align="right"><span class="bold">Date: </span>08/26/2024</td></tr><tr><td/><td align="right"><span class="content_span">Generated for Printing/Faxing/eTransmitting on: 08/29/2024 04:02 PM EDT</span></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></div><br/><br/></body></html>